Press Releases

PHILADELPHIA — (September 24, 2019) — The Wistar Institute was awarded two major grants totaling more than $12 million from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, to fund an international multidisciplinary clinical research consortium spearheaded by Wistar’s HIV Research Program. The consortium, including several partner institutions in the U.S.

PHILADELPHIA — (Sept. 18, 2019) — Researchers at The Wistar Institute have described the role of mitochondrial fission factor (MFF) in controlling survival of cancer cells, suggesting the protein could represent a promising therapeutic target. They also found that expression of MFF is regulated by Myc, a ubiquitous mediator of cell proliferation that contributes to development of many cancer types. These results were published online in the journal EBioMedicine.

PHILADELPHIA — (September 12, 2019) — The Wistar Institute has received a grant of approximately $4.6 million from the National Institutes of Health in support of innovative research to tackle antibiotic resistance.

Inactivation of ARID1A results in loss of telomere cohesion and selects against gross chromosome alterations, preserving genomic stability in ARID1A-mutated cancers.

PHILADELPHIA – (SEPT. 4, 2019) – The Wistar Institute, an international leader in biomedical research in cancer, immunology, infectious diseases, and vaccine creation, and IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage immuno-oncology company, announced today a collaboration to develop a targeted T-cell therapy against a common BRAF cancer mutation. This therapy will be based on peptides identified by Meenhard Herlyn, D.V.M., D.Sc., professor in the Molecular and Cellular Oncogenesis Program and director of Wistar’s Melanoma Research Center.